GSK Drug Candidate Shows Potential in Gynecological Cancers -- Market Talk
Dow Jones
Apr 13
0853 GMT - GSK has released promising data for its drug candidate mo-rez in gynecological cancers that point to another oncology arrow in the U.K. drugmaker's quiver, Jefferies analysts say in a research note. While the drug showed efficacy for ovarian and endometrial cancers with no major safety red flags in early-stage studies, there are caveats about small sample sizes and slightly different prior lines of therapy, Jefferies says. "Ultimately, the key will be demonstrating that this translates to better clinical efficacy--progression-free survival and overall survival benefits--in later-stage studies," the analysts say. Shares fall 0.3%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
April 13, 2026 04:54 ET (08:54 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.